Kazia Therapeutics Limited (KZIA) News
Track canonical SquawkNews coverage tagged to KZIA, Kazia Therapeutics Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Kazia Therapeutics’ Sovargen doses first patient in Phase 1b/2a
Kazia Therapeutics announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders.
EQUITY | Sep 22, 2026, 11:31 AM UTC
L
Kazia Therapeutics price target maintained at $40 by BTIG
BTIG maintained a $40.00 per share price target on Kazia Therapeutics, according to Benzinga/TradingView News ratings actions.
EQUITY | Sep 10, 2026, 01:23 PM UTC
L
Kazia Therapeutics doses first patient in PNOC035 study
Kazia Therapeutics says its first patient was dosed in PNOC035, a clinical study evaluating paxalisib for recurrent pediatric AT/RT brain cancer.
EQUITY | Sep 09, 2026, 11:33 AM UTC
L
Kazia Therapeutics doses first patient in PNOC035 paxalisib AT/RT study
Kazia Therapeutics said the first patient was dosed in its PNOC035 multicenter study evaluating paxalisib plus gemcitabine for recurrent or progressive pediatric AT/RT.
EQUITY | Sep 09, 2026, 11:30 AM UTC
L
Kazia Therapeutics maintained at Buy as BTIG raises target
BTIG maintained Kazia Therapeutics at Buy and raised its price target to $40.00 per share from $34.00, according to Benzinga via TradingView News.
EQUITY | Sep 01, 2026, 03:06 PM UTC
L
Kazia Therapeutics preclinical data links paxalisib to improved immunotherapy response
Kazia Therapeutics reported preclinical data showing paxalisib reprograms immunotherapy-resistant MSS/pMMR colorectal cancer and enhances response to immunotherapy.
EQUITY | Sep 01, 2026, 11:30 AM UTC
L
Kazia Therapeutics preclinical data: paxalisib plus pembrolizumab reduces MSS/pMMR tumors
Preclinical model results show paxalisib monotherapy significantly reduced tumor burden in MSS/pMMR colorectal cancer, with pembrolizumab adding a further reduction. Paxalisib was well tolerated as monotherapy and with c
EQUITY | Sep 01, 2026, 11:30 AM UTC
M
Kazia Therapeutics expands Paxalisib trial into HR+/HER2- breast cancer
Kazia Therapeutics is expanding the Paxalisib clinical trial into HR+/HER2- breast cancer, citing preclinical data supporting strong clinical activity and safety. The three-arm expansion adds Paxalisib plus fulvestrant v
EQUITY | Sep 01, 2026, 11:15 AM UTC
L
Kazia Therapeutics announces oversubscribed closing of up to $120M offering
Kazia Therapeutics Limited said its public offering was oversubscribed and has closed, raising up to $120 million.
EQUITY | Aug 31, 2026, 10:00 PM UTC
L
Kazia Therapeutics prices public offering up to $120 million
Kazia Therapeutics Limited announced pricing of a public offering of up to $120 million.
EQUITY | Aug 28, 2026, 11:30 AM UTC
L
Kazia Therapeutics Shares Fall Following ADS Offering
Kazia Therapeutics Shares Fall Following ADS Offering
EQUITY | Aug 28, 2026, 10:39 AM UTC
M
Kazia Therapeutics announces proposed public offering
Kazia Therapeutics Limited announced a proposed public offering.
EQUITY | Aug 27, 2026, 08:10 PM UTC
L
Kazia Therapeutics reports 100% clinical benefit in initial six patients
Kazia Therapeutics said it saw a 100% clinical benefit rate in its initial six patients treated for advanced triple-negative breast cancer.
CENTRAL_BANK | Aug 27, 2026, 08:02 PM UTC
M
Kazia Therapeutics reports 100% clinical benefit in first six TNBC patients
Kazia Therapeutics said it saw a 100% clinical benefit rate in its initial six treated patients with advanced triple-negative breast cancer.
CENTRAL_BANK | Aug 27, 2026, 08:01 PM UTC
L
Analysts initiate coverage on ACHV, ALGM, KZIA, MTSI, PLYX, SBSW
Several brokers initiate or reiterate bullish coverage on ACHV, ALGM, KZIA, MTSI, PLYX and SBSW, including overweight, buy and strong buy ratings.
EQUITY | Aug 13, 2026, 10:50 AM UTC
L
KZIA Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic
KZIA Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic recurrence in triple-negative breast cancer
EQUITY | Jul 28, 2026, 11:31 AM UTC
L
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA ) with a Buy rating and announces Price Target of $34.
EQUITY | Jul 01, 2026, 11:36 AM UTC